期刊文献+

53例小肠间质瘤的临床分析 被引量:3

Analysis of 53 cases of Small intestinal stromal tumors
下载PDF
导出
摘要 目的:探讨小肠间质瘤的临床表现、诊断及治疗。方法:对某院收治的经病理及免疫组化确诊的53例小肠间质瘤病例的临床表现、病理及诊治进行回顾分析。结果:53例SIST主要临床表现依次为:贫血,消化道出血,腹痛,腹部肿块,腹胀。免疫组化:CD117阳性率(51/53),CD34阳性率(39/53)。该组患者均行手术治疗,中位随访时间32个月(4~60个月)。32例术后复发转移,11例复发转移患者用甲磺酸伊马替尼治疗有效。结论:小肠间质瘤临床表现缺乏特异性;CT诊断小肠间质瘤检出率较高;中高恶性度SIST较低恶性度者更容易复发转移;手术为该病目前最佳选择;甲磺酸伊马替尼对手术不能完全切除及术后复发转移患者有效。 Objective :To evaluate the clinical manifestaion and diagnosis and treatment of small intestinal stromal tumors.Methods:53 cases of small intestinal stromal tumors admitted in some hospital were diagnosed by pathology and immunohistochemistry.Tese cases were analyzed retrospectively with clinical manifestaion and pathology,and with diagnosis and treatment.Results:The main clinical manifestations of SIST included anemia,gastrointestinal bleeding, abdominal pain,abdominal mass,and abdominal distension .Based On Immunohistochemistry,CDll7-positive was seen in 51 patinets (51/53),CD3d-positive was seen in 39 patients (39/53).All patients were managed by surgical management).During the follow-up of 32months (ranging from 4 to 60 months).32 patients had postoperative reccur- rence or metastasis,but the treatment with lmatinib was effective in 11 patients.Conclusions: The clinical manifesta- tions of small intestinal stromal tumors are nonspecific. CT have a high positive rates of diagnostic for SIST.There are higher rate of recurrence and metastase in the high malignant SIST than in the low malignant SIST.The most effective therapy of SIST is operation at present.Imatinib mesylate showed good clinical efect for patients with incompletely re- sectable tumors, postoperative reccurrence or metastasis.
出处 《安徽卫生职业技术学院学报》 2013年第1期38-39,73,共3页 Journal of Anhui Health Vocational & Technical College
关键词 小肠间质瘤 临床表现 诊断 治疗 Small intestinal stromal tumors Clinical manifestation Diagnosis Treatment
  • 相关文献

参考文献8

  • 1Miettinen M.Sobin L H,Sarlomo Rikala M. lmmunohisto chemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CDll7 (kit) [J].Mod Pathol,2000,13 (10):1134-1142. 被引量:1
  • 2Rossi CR,Mocellin S,Mencarelli R,et al.Gas- trointestinal stromal tumors: from a surgical to a molecular approach [J].Int J Cancer,2003,107 (2): 171-176. 被引量:1
  • 3白月奎,邵永孚,石素胜,高燕宁,孙耘田,万玉良.小肠间质瘤预后因素分析[J].中华胃肠外科杂志,2005,8(3):213-216. 被引量:16
  • 4Guy J, BurkiH J, Mohamed M, et al.Malignant gastrointestinal stromal tumor:Distribution,imaging features and pattern of metastatic spread[J].Radiology, 2003,226(2) : 527-532. 被引量:1
  • 5Safdar A, Sher A.Role of c-kiCSCF in cause and treatment of gastrointestinal stromal tunmors(GIST) [J]. GENE.2007,401 : 38-45. 被引量:1
  • 6达明绪,罗婷,钱昆,伍晓汀.胃肠间质瘤研究进展[J].华西医学,2005,20(3):589-591. 被引量:7
  • 7聂明明,沈贤,柴琛,经纬,马立业,毕建威.小肠间质瘤临床诊断和治疗[J].临床肿瘤学杂志,2006,11(5):367-370. 被引量:6
  • 8Dimhofer S,Leyvraz S.Current standards and progress in understanding and treatment of GIST [J]. Swiss Med Wkly,2009, 139(7/8): 90-102. 被引量:1

二级参考文献63

  • 1黄祥成,巴明臣,卿三华,闻英,李国新.空肠回肠间质瘤的诊断和治疗[J].腹部外科,2004,17(5):282-283. 被引量:5
  • 2Singer S,Rubin BP,Lux ML,et al. Prognostic value of KIT mutation type,mitotic activity,and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol,2002,20:3898- 3905. 被引量:1
  • 3Crosby JA,Catton CN,Davis A,et al. Malignant gastrointestinal stromal tumors of the small intestine:a review of 50 cases from a prospective database. Ann Surg Oncol,2001,8:50- 59. 被引量:1
  • 4DeMatteo RP,Lewis JJ,Leung D,et al. Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival. Ann Surg,2000,231:51- 58. 被引量:1
  • 5Clary BM,DeMatteo RP,Lewis JJ,et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum:a clinical comparison. Ann Surg Oncol,2001,8:290- 299. 被引量:1
  • 6Emory TS,Sobin LH,Lukes L,et al. Prognosis of gastrointestinal smooth- muscle (stromal) tumors:dependence on anatomic site. Am J Surg Pathol,1999,23:82- 87. 被引量:1
  • 7Yan H,Marchettini P,Acherman YI,et al. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol,2003,26:221- 228. 被引量:1
  • 8Verweij J,van Oosterom A,Blay JY,et al. Imatinib mesylate (STI- 571 Glivec,Gleevec) is an active agent for gastrointestinal stromal tumours,but does not yield responses in other soft- tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase Ⅱ Study. Eur J Cancer,2003,39:2006- 2011. 被引量:1
  • 9Rudolph P,Gloeckner K,Parwaresch R,et al. Immunophenotype,proliferation,DNA ploidy,and biological behavior of gastroi- ntestinal stromal tumors:a multivariate clinicopathologic study. Hum Pathol,1998,29:791- 800. 被引量:1
  • 10Cunningham RE,Abbondanzo SL,Chu WS,et al. Apoptosis,bcl- 2 expression,and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol,2001, 9:19- 23. 被引量:1

共引文献24

同被引文献30

  • 1徐熙善,朱寿田,洪中武.胃肠道间质瘤的临床表现及诊断[J].实用肿瘤学杂志,2005,19(3):205-206. 被引量:2
  • 2陈群林,孙辉红,陈益光.胃肠道间质瘤的X线和CT表现[J].中国中西医结合影像学杂志,2005,3(3):184-186. 被引量:20
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:86
  • 4陈灏珠,钟南山,陆再英,等.内科学.第8版.北京:人民卫生出版社,2014:7-12. 被引量:4
  • 5Miettinen M, Sobin L H, Sarlomo Rikala M. Immunohisto chemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CDllT(kit) [J]. Mod Pathol, 2000, 13 (10): 1134. 被引量:1
  • 6MazurMT, ClarkHB. Gastric stromal tumors reappraisal of histogene-sis[J]. Am J Surg Pathol, 1983,7(6):507-519. 被引量:1
  • 7Ha HK, Shin JH, Rha SE, eta1. Mod-ified small- bowel follow-through use of methyl cellulose to improve bowel trans radiance and prepare barium suspen-sion[J]. Radiology, 1999, 211(1): 197-201. 被引量:1
  • 8HeinrichM, CorlessC, Demetri G, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J].J Clin Oncol, 2003, 21 (23): 4342. 被引量:1
  • 9Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent ad- vances in pathology and genetics[ J]. Pathol Int,2015,65( 1 ) :9- 18. 被引量:1
  • 10Blay J'Y, Shen L, Kang YK, et al. Nilotinib versus imatinib as first- line therapy for patients with unresectable or metastatic gastroin- testinal stromal turnouts ( ENESTgl ) : a randomised phase 3 trim [J]. Lancet Oncol,2015,16(5) :550-560. 被引量:1

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部